WuXi AppTec, a leading global contract research, development, and manufacturing organization (CRDMO) presented 13 scientific posters at the 2026 Annual Meeting of the American Association for Cancer Research (AACR), held April 17–22 in San Diego, CA. The company demonstrated how its integrated discovery platform helps partners accelerate drug development across multiple modalities and therapeutic targets. The research covered three areas: integrated high-throughput drug discovery, R&D of emerging modalities, including targeted protein degradation (TPD) and mRNA-LNP delivery, and cancer resistance mechanisms and overcoming strategies.
Can WuXi AppTec's Integrated Discovery Platform Power Oncology?
WuXi AppTec's integrated platform combines high-authority screening, pharmacology, and early assessment in a single end-to-end system.
At AACR, WuXi AppTec demonstrated this integration through a study combining high-throughput screening with early therapeutic index determination and safety profiling. This approach enables simultaneous assessment of efficacy and multi organ toxicity, addressing major drivers of late-stage failure and thereby accelerating go/no go decisions. WuXi AppTec's platform also supports parallel evaluation across multiple modalities and targets within a single discovery stage. In one example, WuXi AppTec deployed an integrated high-throughput screening system that combines both cell-free and cell-based assays to evaluate inhibitory activities of small molecules, peptides, antibodies, and ADCs against multiple RGD binding integrins, boosting screening throughput while improving predictive accuracy for downstream activity.
Together, these capabilities show how WuXi AppTec's integrated platform drives progression, accelerates timelines, and improves the decision-making precision of early discovery.
WuXi AppTec's Capabilities in Targeted Protein Degradation (TPD), mRNA-LNP, and Emerging Oncology Modalities
WuXi AppTec's integrated platform supports a broad range of emerging modalities, including targeted protein degradation (TPD), oligonucleotide therapeutics, and immune-based strategies.
In TPD, WuXi AppTec integrated focused library design, targeted assays, structural biology, and direct-to-biology (D2B) high-throughput optimization to enable the exploration of novel E3 ligases beyond classical E3 ligases. Research presented at AACR 2026 demonstrated this approach applies to GID4, a non-classical E3 ligase, expanding the range of druggable targets and opening new therapeutic opportunities.
In mRNA-LNP delivery, WuXi AppTec developed a selective organ-targeting lipid nanoparticle (SORT LNP) and formulated mRNA encoding a T-cell-engaging bispecific antibody. The construct binds the T-cell marker and bivalently targets epithelial cell adhesion molecule (EpCAM), demonstrating more than a tenfold increase in T-cell activation in vitro. In vivo, it significantly reversed tumor growth within four days, with no apparent adverse effects observed. These results highlight its potential application value in solid tumors.
WuXi AppTec also presented data on combination immunotherapy strategies, showing that pairing T-cell engagers with immune checkpoint inhibitors increased anti-tumor efficacy by up to more than sevenfold in humanized small cell lung cancer (SCLC) models.
How WuXi AppTec Addresses Cancer Drug Resistance: ADCs, BTK Degraders, BCL-2 Inhibitors, and KRAS
Cancer drug resistance remains a major barrier to durable treatment outcomes. WuXi AppTec's platform integrates disease-relevant tumor models with therapeutic validation to identify resistance mechanisms and develop new strategies to overcome it.
Studies presented at AACR covered resistance across four drug classes:
- ADCs — Profiling of ADC-resistant cancer models reveals both target-driven resistance mechanisms, including HER2 downregulation, and diverse resistance mechanisms across different ADCs and tumor models.
- BTK Inhibitors — In B-cell malignancies, evaluation has been conducted in the efficacy of the novel CRBN E3 ligase mediated BTK degrader, suggesting the targeted protein degraders can eliminate mutant BTK proteins associated with resistance to covalent inhibitors.
- BCL-2 Inhibitors — In acute myeloid leukemia, resistance to BCL-2 inhibitors is linked to alternative survival pathways such as MCL-1, and combination strategies have demonstrated the potential to restore sensitivity.
- KRAS G12D Inhibitors — Integrated analyses reveal diverse resistance mechanism to KRAS G12D inhibition including secondary mutations, signaling rewiring, and metabolic adaptation, providing a foundation for biomarker development and rational combination therapies.
WuXi AppTec at AACR 2026: Key Findings
The research presented at AACR 2026 highlights a consistent theme: integration is a prerequisite for modern oncology drug discovery, not just an operational advantage. By connecting discovery, evaluation, and translational insight within one platform, WuXi AppTec enables partners to move forward with greater speed, clarity, and confidence — so that "every drug can be made, and every disease can be treated."
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (contract research, development, and manufacturing organization) platform. We are privileged to work alongside partners across 30-plus countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients — one collaboration at a time. Learn more at www.wuxiapptec.com.
Media Contact
Media Contact
mediainquiries@wuxiapptec.com
